Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-25-029507
Filing Date
2025-02-28
Accepted
2025-02-28 07:00:18
Documents
105
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K apls-20241231.htm   iXBRL 10-K 4354685
2 EX-21.1 apls-ex21_1.htm EX-21.1 26285
3 EX-23.1 apls-ex23_1.htm EX-23.1 3524
4 EX-31.1 apls-ex31_1.htm EX-31.1 17419
5 EX-31.2 apls-ex31_2.htm EX-31.2 17429
6 EX-32.1 apls-ex32_1.htm EX-32.1 9984
7 EX-32.2 apls-ex32_2.htm EX-32.2 9727
8 GRAPHIC img139103030_0.jpg GRAPHIC 89803
9 GRAPHIC img139103030_1.jpg GRAPHIC 49742
10 GRAPHIC img139103030_2.jpg GRAPHIC 60321
11 GRAPHIC img139103030_3.jpg GRAPHIC 77667
12 GRAPHIC img139103030_4.jpg GRAPHIC 163945
  Complete submission text file 0000950170-25-029507.txt   17255085

Data Files

Seq Description Document Type Size
13 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT apls-20241231.xsd EX-101.SCH 2267675
108 EXTRACTED XBRL INSTANCE DOCUMENT apls-20241231_htm.xml XML 2830659
Mailing Address 100 FIFTH AVENUE WALTHAM MA 02451
Business Address 100 FIFTH AVENUE WALTHAM MA 02451 617-977-5700
Apellis Pharmaceuticals, Inc. (Filer) CIK: 0001492422 (see all company filings)

EIN.: 271537290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-38276 | Film No.: 25682513
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)